Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVA NASDAQ:MGTX NASDAQ:OPT NASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVAInventiva$5.55+3.5%$3.99$1.53▼$6.50$530.92M0.6923,427 shs22,177 shsMGTXMeiraGTx$7.76+1.4%$7.94$3.86▼$8.98$623.87M1.29511,764 shs145,750 shsOPTOpthea$3.41$3.41$1.79▼$6.30$583.11M1.17N/AN/ATHTXTheratechnologies$3.28+0.2%$3.18$1.12▼$3.28$150.58M0.511.33 million shs87,597 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVAInventiva-0.19%+1.90%+49.72%+51.41%+143.64%MGTXMeiraGTx+2.41%+4.79%-2.92%+18.06%+90.30%OPTOpthea0.00%0.00%0.00%0.00%+8.60%THTXTheratechnologies0.00%+0.93%+2.51%+28.24%+165.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVAInventiva$5.55+3.5%$3.99$1.53▼$6.50$530.92M0.6923,427 shs22,177 shsMGTXMeiraGTx$7.76+1.4%$7.94$3.86▼$8.98$623.87M1.29511,764 shs145,750 shsOPTOpthea$3.41$3.41$1.79▼$6.30$583.11M1.17N/AN/ATHTXTheratechnologies$3.28+0.2%$3.18$1.12▼$3.28$150.58M0.511.33 million shs87,597 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVAInventiva-0.19%+1.90%+49.72%+51.41%+143.64%MGTXMeiraGTx+2.41%+4.79%-2.92%+18.06%+90.30%OPTOpthea0.00%0.00%0.00%0.00%+8.60%THTXTheratechnologies0.00%+0.93%+2.51%+28.24%+165.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVAInventiva 2.83Moderate Buy$14.83167.27% UpsideMGTXMeiraGTx 3.00Buy$24.00209.48% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideTHTXTheratechnologies 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest THTX, IVA, MGTX, and OPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.007/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVAInventiva$9.20M57.72N/AN/A($1.21) per share-4.59MGTXMeiraGTx$37.92M16.45N/AN/A$0.87 per share8.91OPTOpthea$30K19,437.00N/AN/A($1.31) per share-2.60THTXTheratechnologies$84.38M1.78N/AN/A($0.55) per share-5.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A20.41N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)OPTOpthea-$162.79MN/A0.00N/AN/AN/AN/AN/A9/12/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.19N/A46.79N/A-10.85%N/A-9.83%10/9/2025 (Estimated)Latest THTX, IVA, MGTX, and OPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A9/12/2025H2 2025OPTOpthea-$0.0456N/AN/AN/A$0.07 millionN/A8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.09-$0.08-$0.09$24.30 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIVAInventivaN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVAInventivaN/A0.920.92MGTXMeiraGTx26.290.880.88OPTOptheaN/A0.22N/ATHTXTheratechnologiesN/A0.840.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVAInventiva19.06%MGTXMeiraGTx67.48%OPTOpthea55.95%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipIVAInventiva32.00%MGTXMeiraGTx7.50%OPTOpthea3.20%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVAInventiva10095.66 million65.05 millionNot OptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableOPTOpthea8171.00 million165.53 millionNot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableTHTX, IVA, MGTX, and OPT HeadlinesRecent News About These CompaniesShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Expands By 31.4%September 10 at 2:58 AM | marketbeat.comTheratechnologies announces availability of EGRIFTA WRSeptember 6, 2025 | msn.comTheratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and LipodystrophySeptember 5, 2025 | globenewswire.comNantahala Capital Management LLC Cuts Stake in Theratechnologies Inc. $THTXSeptember 3, 2025 | marketbeat.comTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future PakSeptember 2, 2025 | globenewswire.comTheratechnologies Inc. (NASDAQ:THTX) Sees Significant Drop in Short InterestAugust 23, 2025 | marketbeat.comTheratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future PakAugust 18, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the Second Quarter 2025July 9, 2025 | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7, 2025 | seekingalpha.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3, 2025 | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3, 2025 | globenewswire.comTheratechnologies to be Acquired by Future Pak AffiliateJuly 2, 2025 | tipranks.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | finance.yahoo.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 29, 2025 | globenewswire.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?By Nathan Reiff | August 11, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025THTX, IVA, MGTX, and OPT Company DescriptionsInventiva NASDAQ:IVA$5.55 +0.19 (+3.54%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.MeiraGTx NASDAQ:MGTX$7.76 +0.11 (+1.37%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 09/9/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Theratechnologies NASDAQ:THTX$3.28 +0.01 (+0.15%) As of 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
